Evidence map›Paper›PMID 27929735›Full record

ArticlemAbs

Development of adsorptive hybrid filters to enable two-step purification of biologics.

Nripen Singh, Abhiram Arunkumar, Michael Peck, Alexei M Voloshin, Angela M Moreno, Zhijun Tan, Jonathan Hester, Michael C Borys, Zheng Jian Li

Abstract read
In one paragraph

Article in mAbs. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. DNA RETENTION ON DEPTH FILTERS.Journal of membrane science · 2019
    Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Nripen Singha Biologics Development, Global Manufacturing and Supply, Bristol-Myers Squibb Company , Devens , MA , USA.
Abhiram Arunkumara Biologics Development, Global Manufacturing and Supply, Bristol-Myers Squibb Company , Devens , MA , USA.
Michael Pecka Biologics Development, Global Manufacturing and Supply, Bristol-Myers Squibb Company , Devens , MA , USA.
Alexei M Voloshinb Life Science Process Technologies, 3M Purification Inc. , St Paul , MN , USA.
Angela M Morenob Life Science Process Technologies, 3M Purification Inc. , St Paul , MN , USA.
Zhijun Tana Biologics Development, Global Manufacturing and Supply, Bristol-Myers Squibb Company , Devens , MA , USA.
Jonathan Hesterb Life Science Process Technologies, 3M Purification Inc. , St Paul , MN , USA.
Michael C Borysa Biologics Development, Global Manufacturing and Supply, Bristol-Myers Squibb Company , Devens , MA , USA.
Zheng Jian Lia Biologics Development, Global Manufacturing and Supply, Bristol-Myers Squibb Company , Devens , MA , USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recent progress in mammalian cell culture process has resulted in significantly increased product titers, but also a substantial increase in process- and product-related impurities. Due to the diverse physicochemical properties of these impurities, there is constant need for new technologies that offer higher productivity and improved economics without sacrificing the process robustness required to meet final drug substance specifications. Here, we examined the use of new synthetic adsorptive hybrid filters (AHF) modified with the high binding capacity of quaternary amine (Emphaze™ AEX) and salt-tolerant biomimetic (Emphaze™ ST-AEX) ligands for clearance of process-related impurities like host cell protein (HCP), residual DNA, and virus. The potential to remove soluble aggregates was also examined. Our aim was to develop a mechanistic understanding of the interactions governing adsorptive removal of impurities during filtration by evaluating the effect of various filter types, feed streams, and process conditions on impurity removal. The ionic capacity of these filters was measured and correlated with their ability to remove impurities for multiple molecules. The ionic capacity of AHF significantly exceeded that of traditional adsorptive depth filters (ADF) by 40% for the Emphaze™ AEX and by 700% for the Emphaze™ ST-AEX, providing substantially higher reduction of soluble anionic impurities, including DNA, HCPs and model virus. Nevertheless, we determined that ADF with filter aid provided additional hydrophobic functionality that resulted in removal of higher molecular weight species than AHF. Implementing AHF demonstrated improved process-related impurity removal and viral clearance after Protein A chromatography and enabled a two-step purification process. The consequences of enhanced process performance are far reaching because it allows the downstream polishing train to be restructured and simplified, and chromatographic purity standards to be met with a reduced number of chromatographic steps.

Indexed as

AnimalsAntibodies, MonoclonalBiological ProductsBiotechnologyCHO CellsChromatography, Ion ExchangeCricetinaeCricetulusDrug ContaminationFiltrationAntibodies, MonoclonalBiological ProductsAdsorptive filtersclarificationhybrid filtersprocess compressionpurificationviral clearance

Identifiers

PMID27929735
PMCPMC5297532

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.